What Is the Newly Approved Non‑Stimulant ADHD Medication?

PostedSeptember 22, 2025

UpdatedSeptember 22, 2025

ByMy Patient Advice

Author: Avery Lombardi, MSc | Reviewed by: Dr. Rebecca Fernandez, MBBS

The new non-stimulant ADHD medication recently approved by the FDA is Viloxazine (brand name Qelbree). Approved in 2021, it offers an alternative treatment option for individuals with ADHD, particularly those who do not respond well to stimulants or prefer non-stimulant options.

FDA Approval and Mechanism of Action

Viloxazine was granted FDA approval after clinical trials demonstrated its effectiveness in treating ADHD in children and adolescents. Unlike traditional stimulants, Viloxazine works by targeting norepinephrine and serotonin receptors in the brain. This action helps regulate mood and attention, providing steady symptom relief over time. The new non-stimulant ADHD medication helps control symptoms like inattention, hyperactivity, and impulsivity without the immediate onset and side effects associated with stimulants.

Treatment Options and Benefits

One of the key benefits of Viloxazine is that it provides an effective treatment option for those who experience side effects from stimulant medications, such as insomnia, appetite suppression, or anxiety. It is also a safer alternative for individuals with a history of substance misuse since it does not carry the same risk of addiction. The medication offers a more gradual improvement in symptoms compared to stimulants, and it works throughout the day with a relatively mild side effect profile.

Side Effects

Common side effects of Viloxazine include decreased appetite, fatigue, and irritability, but these are generally well-tolerated compared to those seen with stimulants.

In conclusion, Viloxazine is the new non-stimulant ADHD medication that provides an alternative for individuals seeking consistent symptom relief without the concerns of stimulant medications.

Visit providers like ADHD Certify for personal consultations and expert guidance tailored to your unique situation.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medications for ADHD.

Avery Lombardi, MSc

Author

Avery Lombardi is a clinical psychologist with a Master’s in Clinical Psychology and a Bachelor’s in Psychology. She has professional experience in psychological assessment, evidence-based therapy, and research, working with both child and adult populations. Avery has provided clinical services in hospital, educational, and community settings, delivering interventions such as CBT, DBT, and tailored treatment plans for conditions including anxiety, depression, and developmental disorders. She has also contributed to research on self-stigma, self-esteem, and medication adherence in psychotic patients, and has created educational content on ADHD, treatment options, and daily coping strategies.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.